Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Cholangiocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Oncogenic osteomalacia 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Hypophosphatemia 1Hematologic Neoplasms 1Glioblastoma 1Acrocephalosyndactylia 1

Interventions

Cisplatin 18Radiotherapy 9Gemcitabine 8Fluorouracil 8Docetaxel 7Paclitaxel 6Carboplatin 5Capecitabine 5Radiotherapy, Intensity-Modulated 4Oxaliplatin 4Nivolumab 3Endostatins 3Bevacizumab 3toripalimab 2spartalizumab 2pembrolizumab 2endostar protein 2apatinib 2Cetuximab 2Celecoxib 2triethanolamine 1sintilimab 1regramostim 1penpulimab 1infigratinib 1fluzoparib 1cc-486 1camrelizumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Neoplasms × infigratinib × Clear all
NCT02706691 2019-04-16

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

University of Chicago

Phase 2 Terminated
1 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡